Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili study. Gray, G. E, Moodie, Z., Metch, B., Gilbert, P. B, Bekker, L., Churchyard, G., & et al. The Lancet Infectious Diseases, 14(5):388–396, Elsevier, 2014.
bibtex   
@article{Grayetal2014short,
  title={Recombinant adenovirus type 5 {HIV} gag/pol/nef vaccine in {South Africa}: unblinded, long-term follow-up of the phase 2b {HVTN 503/Phambili} study},
  author={Gray, Glenda E and Moodie, Zoe and Metch, Barbara and Gilbert, Peter B and Bekker, Linda-Gail and Churchyard, Gavin and et al.},
  journal={The Lancet Infectious Diseases},
  volume={14},
  number={5},
  pages={388--396},
  year={2014},
  publisher={Elsevier}
}

Downloads: 0